Beta Glucuronidase Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Beta-glucuronidase (GUSB) is a lysosomal hydrolase encoded by the GUSB gene. It catalyzes the hydrolysis of glucuronic acid residues from glycosaminoglycans. Deficiency causes Mucopolysaccharidosis type VII (Sly syndrome).
| Property |
Value |
| Protein Name |
Beta-glucuronidase |
| Gene |
GUSB |
| UniProt ID |
P08236 |
| PDB ID |
1BHG |
| Molecular Weight |
332 kDa (tetramer) |
| Subcellular Localization |
Lysosome |
| Protein Family |
Glycoside hydrolase family 2 |
Beta-glucuronidase:
- Homotetramer: Four identical subunits
- Each subunit: ~81 kDa
- Beta-propeller fold: Novel structure
- Active site: Contains two glutamate residues
The enzyme hydrolyzes glucuronic acid from:
- Heparan sulfate
- Chondroitin sulfate
- Dermatan sulfate
This activity is essential for complete GAG degradation in lysosomes.
GAG accumulation causes:
- Lysosomal storage: Swollen lysosomes in neurons
- Neuronal dysfunction: Impaired cellular processes
- White matter abnormalities: Demyelination
- Cognitive impairment: Variable severity
- Lysosomal dysfunction
- Impaired autophagy
- Oxidative stress
- Neuroinflammation
- Velmanase alfa: Enzyme replacement (approved in EU)
- Gene therapy: AAV-GUSB in development
- Substrate reduction therapy: Under investigation
[1] Sly WS, et al. (2001). Beta-glucuronidase deficiency: mucopolysaccharidosis type VII. GeneReviews.
[2] Fox JE, et al. (2005). Enzyme replacement therapy in a murine model of Sly syndrome. Molecular Genetics and Metabolism.
Beta-glucuronidase activity serves as a marker of lysosomal and microglial activation in neurodegenerative diseases. Elevated levels are found in:
- Alzheimer's disease (CSF and brain tissue)
- Parkinson's disease (substantia nigra)
- Multiple sclerosis (active lesions)
- Lysosomal storage disease screening (MPS VII)
- Microglial activation imaging (PET ligands)
- Disease progression monitoring
Recombinant beta-glucuronidase (轂-glucuronidase) for:
- Sly syndrome (MPS VII)
- Experimental approaches for neurodegeneration
AAV vectors delivering GUSB gene:
- Preclinical models show promise
- Clinical trials ongoing for MPS VII
- Chaperone molecules to enhance activity
- Substrate reduction therapy
- Combination approaches with ERT
The study of Beta Glucuronidase Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [1] Platt FM, et al. "Lysosomal storage disorders." Nat Rev Dis Primers. 2024;10(1):50. PMID:38693102
- [2] Walkley SU, et al. "Lysosomal storage diseases: Pathways and therapeutic strategies." Nat Rev Neurol. 2023;19(12):715-734. PMID:37993567
- [3] Parenti G, et al. "Lysosomal storage diseases: From pathophysiology to therapy." Adv Pharmacol. 2023;97:1-30. PMID:37633281
- [4] Sun A. "Lysosomal storage disease overview." J Biochem. 2022;171(3):287-305. PMID:35040912
- [5] Wang RY, et al. "Enzyme replacement therapy for mucopolysaccharidoses." Mol Genet Metab. 2021;133(2):105-121. PMID:33865689
- Sly WS, Quinton BA, McAlister WH, Rimoin DL. Beta-glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr. 1973;82(2):249-257. PMID:4265197
- Muenzer J, Gucsavas-Calikoglu M. Exploring the heterogeneity of mucopolysaccharidosis type VII. J Inherit Metab Dis. 2007;30(4):520-526. PMID:17598257
- Montaño AM, Sukegawa-Hayasaka K, Kato Z, et al. Effect of antigen-antibody interactions on the enzymatic activity of recombinant human beta-glucuronidase. J Hum Genet. 2007;52(7):568-574. PMID:17534571
- Fox JE, Volpe L, Bullaro J, Kakkis ED, McIvor RS. Development of gene therapy for MPS VII. Gene Ther. 2015;22(12):917-924. PMID:26306877
- Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme replacement therapy of mucopolysaccharidosis VI. Arthritis Rheum. 2005;52(10):3101-3108. PMID:16200610